[Recent findings in dermatophytic skin diseases (author's transl)].
The most important current research centers on immunobiological questions. It is suggested that the delayed Trichophyton reaction is the immune mechanism which protects patients after a primary dermatophyte infection. Griseofulvin is the treatment of choice today. The questionnaire sent to all practising dermatologists in Germany investigated the frequency of certain possible serious side effects. The new once daily 500 mg griseofulvin tablet will have to be in clinical use for some time yet before its efficacy can be assessed.
D003881:Dermatomycoses / Q000188:drug therapy*; D005860:Germany, West; D006118:Griseofulvin / Q000627:therapeutic use*; D006801:Humans; D007136:Immunoglobulins / Q000032:analysis; D009154:Mutation; D012775:Shoes; D014005:Tinea / Q000453:epidemiology; D014008:Tinea Pedis / Q000517:prevention & control; D014249:Trichophyton / Q000276:immunology
D007136:Immunoglobulins; D006118:Griseofulvin
Neuere Befunde über Hautkrankheiten durch Dermatophyten.